JP2017505794A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505794A5 JP2017505794A5 JP2016551294A JP2016551294A JP2017505794A5 JP 2017505794 A5 JP2017505794 A5 JP 2017505794A5 JP 2016551294 A JP2016551294 A JP 2016551294A JP 2016551294 A JP2016551294 A JP 2016551294A JP 2017505794 A5 JP2017505794 A5 JP 2017505794A5
- Authority
- JP
- Japan
- Prior art keywords
- tert
- butyl
- pyrazol
- naphthalen
- pyridin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2019162164A JP6952085B2 (ja) | 2014-02-14 | 2019-09-05 | キナーゼ阻害剤としてのピラゾリル尿素 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461940282P | 2014-02-14 | 2014-02-14 | |
| US61/940,282 | 2014-02-14 | ||
| US201461941064P | 2014-02-18 | 2014-02-18 | |
| US61/941,064 | 2014-02-18 | ||
| PCT/GB2015/050401 WO2015121660A1 (en) | 2014-02-14 | 2015-02-13 | Pyrazolyl-ureas as kinase inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162164A Division JP6952085B2 (ja) | 2014-02-14 | 2019-09-05 | キナーゼ阻害剤としてのピラゾリル尿素 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017505794A JP2017505794A (ja) | 2017-02-23 |
| JP2017505794A5 true JP2017505794A5 (cg-RX-API-DMAC10.html) | 2019-04-04 |
| JP6586098B2 JP6586098B2 (ja) | 2019-10-02 |
Family
ID=52573661
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550815A Active JP6630280B2 (ja) | 2014-02-14 | 2015-02-13 | 抗炎症化合物としての芳香族複素環化合物 |
| JP2016551294A Active JP6586098B2 (ja) | 2014-02-14 | 2015-02-13 | キナーゼ阻害剤としてのピラゾリル尿素 |
| JP2019162164A Active JP6952085B2 (ja) | 2014-02-14 | 2019-09-05 | キナーゼ阻害剤としてのピラゾリル尿素 |
| JP2019220267A Active JP6841891B2 (ja) | 2014-02-14 | 2019-12-05 | 抗炎症化合物としての芳香族複素環化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016550815A Active JP6630280B2 (ja) | 2014-02-14 | 2015-02-13 | 抗炎症化合物としての芳香族複素環化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019162164A Active JP6952085B2 (ja) | 2014-02-14 | 2019-09-05 | キナーゼ阻害剤としてのピラゾリル尿素 |
| JP2019220267A Active JP6841891B2 (ja) | 2014-02-14 | 2019-12-05 | 抗炎症化合物としての芳香族複素環化合物 |
Country Status (20)
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ586418A (en) | 2007-12-19 | 2012-09-28 | Cancer Rec Tech Ltd | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| EP2531502B1 (en) | 2010-02-01 | 2014-04-02 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| WO2013050757A1 (en) | 2011-10-03 | 2013-04-11 | Respivert Limited | 1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
| EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| EP2970190A1 (en) | 2013-03-14 | 2016-01-20 | Respivert Limited | Kinase inhibitors |
| EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| DK2981526T3 (da) | 2013-04-02 | 2022-02-07 | Oxular Acquisitions Ltd | Naphthylureaderivater til anvendelse som kinaseinhibitorer |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| US9890185B2 (en) | 2013-12-20 | 2018-02-13 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| PT3105222T (pt) | 2014-02-14 | 2018-07-18 | Respivert Ltd | Compostos heterocíclicos aromáticos como compostos anti-inflamatórios |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| CN105801486A (zh) * | 2016-03-31 | 2016-07-27 | 常州大学 | 一种1-（2,4二溴苯基）-3-吡唑醇的合成方法 |
| CN109071505B (zh) | 2016-04-06 | 2021-11-16 | 奥苏拉收购有限公司 | 激酶抑制剂 |
| WO2017223284A1 (en) | 2016-06-23 | 2017-12-28 | University Of Maryland, Baltimore | NON-CATALYTIC SUBSTRATE-SELECTIVE P38α-SPECIFIC MAPK INHIBITORS WITH ENDOTHELIAL-STABILIZING AND ANTI-INFLAMMATORY ACTIVITY, AND METHODS OF USE THEREOF |
| EP3558363A1 (en) | 2016-12-21 | 2019-10-30 | Amgen Inc. | Anti-tnf alpha antibody formulations |
| EP3691620B1 (en) | 2017-10-05 | 2022-07-27 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce dux4 and downstream gene expression for the treatment of fshd |
| US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
| JP7594787B2 (ja) | 2018-12-07 | 2024-12-05 | ユニバーシティ オブ メリーランド、ボルチモア | 非ＡＴＰ／触媒部位ｐ３８マイトジェン活性化プロテインキナーゼ阻害剤 |
| CA3125039A1 (en) * | 2019-01-23 | 2020-07-30 | Theravance Biopharma R&D Ip, Llc | Imidazo[1,5-a]pyridine, 1,2,4-triazolo[4,3-a]pyridine and imidazo[1,5-a]pyrazine as jak inhibitors |
| CN116406355A (zh) | 2020-05-18 | 2023-07-07 | Gen1E生命科学公司 | P38α促分裂原活化蛋白激酶抑制剂 |
| CN111889025B (zh) * | 2020-09-01 | 2022-01-11 | 山东大学 | 一种耐酸碱耐盐超两亲分子乳化剂及其制备方法和乳液 |
| AU2021370893B2 (en) | 2020-10-29 | 2024-03-07 | Gen1E Lifesciences Inc. | Crystalline 5-(dimethylamino) -n- (4-(morpholinomethyl)phenyl) naphthalene-1-sulfonamide di-hydrochloride di-hydrate |
| AU2022215580A1 (en) * | 2021-02-03 | 2023-08-10 | Bp Asset V, Inc. | Formulation of furin inhibitor for inhalation |
| JP7659650B2 (ja) | 2021-03-23 | 2025-04-09 | ジーニー ライフサイエンシズ インコーポレイテッド | 置換ナフチルｐ３８アルファマイトジェン活性化プロテインキナーゼ阻害剤 |
| CN116655608B (zh) * | 2023-05-30 | 2025-08-19 | 成都瑞芬思德丹生物科技有限公司 | 一种具有抗炎活性的吡咯烷酮类化合物及其制备方法和应用 |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080300281A1 (en) | 1997-12-22 | 2008-12-04 | Jacques Dumas | Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas |
| ID26328A (id) | 1997-12-22 | 2000-12-14 | Bayer Ag | Penghambat raf kinase menggunakan urea heterosiklik tersubstitusi aril dan heteroaril |
| JP2001526222A (ja) | 1997-12-22 | 2001-12-18 | バイエル コーポレイション | アリールおよびヘテロアリール置換複素環尿素を使用するｐ３８キナーゼ活性の阻害 |
| US7329670B1 (en) | 1997-12-22 | 2008-02-12 | Bayer Pharmaceuticals Corporation | Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas |
| UA73492C2 (en) * | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
| WO2001004115A2 (en) | 1999-07-09 | 2001-01-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | Novel process for synthesis of heteroaryl-substituted urea compounds |
| WO2001036403A1 (en) | 1999-11-16 | 2001-05-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Urea derivatives as anti-inflammatory agents |
| US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
| US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
| US6376515B2 (en) | 2000-02-29 | 2002-04-23 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor Xa |
| EP1392661A1 (en) | 2001-05-16 | 2004-03-03 | Boehringer Ingelheim Pharmaceuticals Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
| ATE360417T1 (de) | 2001-07-11 | 2007-05-15 | Boehringer Ingelheim Pharma | Methode zur behandlung von zytokinvermittelten erkrankungen |
| US20030216396A1 (en) | 2002-02-11 | 2003-11-20 | Bayer Corporation | Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors |
| EP1478358B1 (en) | 2002-02-11 | 2013-07-03 | Bayer HealthCare LLC | Sorafenib tosylate for the treatment of diseases characterized by abnormal angiogenesis |
| ES2299689T3 (es) * | 2002-02-25 | 2008-06-01 | Boehringer Ingelheim Pharmaceuticals Inc. | Compuestos de cicloalquil-uera fusionada con benzo 1,4-disustituido, utiles para el tratamiento de enfermedades por citoquinas. |
| WO2004002481A1 (en) | 2002-06-27 | 2004-01-08 | Novo Nordisk A/S | Aryl carbonyl derivatives as therapeutic agents |
| WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ｃｃｒ４アンタゴニストおよびその医薬用途 |
| ES2357288T3 (es) | 2003-02-28 | 2011-04-25 | Bayer Healthcare Llc | Derivados de 2-oxo-1,3,5-perhidrotriazapina útiles en el tratamiento de angiogénesis hiperproliferativa y trastornos inflamatorios. |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| MXPA06012394A (es) | 2004-04-30 | 2007-01-31 | Bayer Pharmaceuticals Corp | Derivados de pirazolilurea sustituidos utiles en el tratamiento de cancer. |
| GB0500435D0 (en) | 2005-01-10 | 2005-02-16 | Novartis Ag | Organic compounds |
| WO2007002635A2 (en) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| JP2010506942A (ja) | 2006-10-20 | 2010-03-04 | イコス・コーポレイション | Ｃｈｋ１阻害剤の組成物 |
| PT2268623E (pt) | 2008-03-17 | 2015-09-17 | Ambit Biosciences Corp | Derivados de quinazolina como moduladores de cinase raf e métodos para utilização dos mesmos |
| GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
| US8293748B2 (en) | 2008-10-02 | 2012-10-23 | Respivert Ltd. | p38 MAP kinase inhibitors |
| EP2370428B1 (en) * | 2008-12-11 | 2016-08-10 | Respivert Limited | P38 map kinase inhibitors |
| GB0905955D0 (en) * | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
| GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
| GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
| ES2676918T3 (es) | 2010-03-15 | 2018-07-26 | Ube Industries, Ltd. | Método para producir un compuesto de amida |
| GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
| JP5787977B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | Ｐ３８ｍａｐキナーゼ阻害剤 |
| EP2556067B1 (en) * | 2010-04-08 | 2016-02-24 | Respivert Limited | Pyrazolyl ureas as p38 map kinase inhibitors |
| EP2582700B1 (en) | 2010-06-17 | 2016-11-02 | Respivert Limited | Respiratory formulations containing p38 mapk inhibitors |
| GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
| GB201010196D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
| EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
| WO2013050757A1 (en) * | 2011-10-03 | 2013-04-11 | Respivert Limited | 1-pyrazolyl-3- (4- ( (2 -anilinopyrimidin- 4 - yl) oxy) napththalen- 1 - yl) ureas as p38 map kinase inhibitors |
| PE20141370A1 (es) | 2011-12-09 | 2014-10-17 | Chiesi Farma Spa | Inhibidores de quinasa |
| GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
| EP2890460B1 (en) | 2012-08-29 | 2017-02-22 | Respivert Limited | Kinase inhibitors |
| EP2890695A2 (en) | 2012-08-29 | 2015-07-08 | Respivert Limited | Kinase inhibitors |
| GB201215357D0 (en) * | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
| EP2890701B1 (en) | 2012-08-29 | 2017-03-29 | Respivert Limited | Kinase inhibitors |
| EP2925742B1 (en) | 2012-11-16 | 2016-10-26 | Respivert Limited | Kinase inhibitors |
| EP2970190A1 (en) | 2013-03-14 | 2016-01-20 | Respivert Limited | Kinase inhibitors |
| DK2981526T3 (da) | 2013-04-02 | 2022-02-07 | Oxular Acquisitions Ltd | Naphthylureaderivater til anvendelse som kinaseinhibitorer |
| EP2981534B1 (en) | 2013-04-02 | 2017-07-19 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
| US9890185B2 (en) | 2013-12-20 | 2018-02-13 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
| PT3105222T (pt) | 2014-02-14 | 2018-07-18 | Respivert Ltd | Compostos heterocíclicos aromáticos como compostos anti-inflamatórios |
| MA40774A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivés de diaryle-urée en tant qu'inhibiteurs de kinase p38 |
| WO2016051186A1 (en) | 2014-10-01 | 2016-04-07 | Respivert Limited | N-phenyl-3-quinazolin-6-yl-benzamide derivatives as p38 kinase inhibitors |
-
2015
- 2015-02-13 PT PT157057977T patent/PT3105222T/pt unknown
- 2015-02-13 EP EP15705797.7A patent/EP3105222B1/en active Active
- 2015-02-13 WO PCT/EP2015/053151 patent/WO2015121444A1/en not_active Ceased
- 2015-02-13 DK DK15705797.7T patent/DK3105222T3/en active
- 2015-02-13 CN CN202110516085.9A patent/CN113264921B/zh active Active
- 2015-02-13 TW TW104104906A patent/TWI751099B/zh active
- 2015-02-13 EA EA201691625A patent/EA034927B1/ru unknown
- 2015-02-13 CN CN201910753454.9A patent/CN110522731B/zh active Active
- 2015-02-13 MX MX2016010572A patent/MX371353B/es active IP Right Grant
- 2015-02-13 PT PT181618695T patent/PT3357919T/pt unknown
- 2015-02-13 MX MX2016010571A patent/MX371312B/es active IP Right Grant
- 2015-02-13 PL PL15705797T patent/PL3105222T3/pl unknown
- 2015-02-13 CN CN201580008529.0A patent/CN106164067B/zh active Active
- 2015-02-13 BR BR112016015838-5A patent/BR112016015838B1/pt active IP Right Grant
- 2015-02-13 TW TW104104905A patent/TWI664967B/zh active
- 2015-02-13 UY UY0001035998A patent/UY35998A/es active IP Right Grant
- 2015-02-13 TR TR2018/09072T patent/TR201809072T4/tr unknown
- 2015-02-13 CN CN201580019810.4A patent/CN106573914B/zh active Active
- 2015-02-13 WO PCT/GB2015/050401 patent/WO2015121660A1/en not_active Ceased
- 2015-02-13 US US14/622,368 patent/US9447076B2/en active Active
- 2015-02-13 US US15/118,708 patent/US9884845B2/en active Active
- 2015-02-13 CA CA2938924A patent/CA2938924C/en active Active
- 2015-02-13 DK DK18161869.5T patent/DK3357919T3/da active
- 2015-02-13 AU AU2015216705A patent/AU2015216705B2/en active Active
- 2015-02-13 KR KR1020167023275A patent/KR102413704B1/ko active Active
- 2015-02-13 PL PL18161869T patent/PL3357919T3/pl unknown
- 2015-02-13 SG SG11201607058PA patent/SG11201607058PA/en unknown
- 2015-02-13 EP EP18186182.4A patent/EP3418279B1/en active Active
- 2015-02-13 EP EP18161869.5A patent/EP3357919B1/en active Active
- 2015-02-13 EP EP15706511.1A patent/EP3105223B1/en active Active
- 2015-02-13 JP JP2016550815A patent/JP6630280B2/ja active Active
- 2015-02-13 JP JP2016551294A patent/JP6586098B2/ja active Active
- 2015-02-13 ES ES15705797.7T patent/ES2677595T3/es active Active
- 2015-02-13 ES ES18161869T patent/ES2774249T3/es active Active
- 2015-02-13 AU AU2015216957A patent/AU2015216957B2/en active Active
- 2015-02-15 JO JOP/2015/0032A patent/JO3392B1/ar active
-
2016
- 2016-08-31 US US15/253,141 patent/US9624196B2/en active Active
-
2017
- 2017-03-13 US US15/457,810 patent/US10045980B2/en active Active
- 2017-12-21 US US15/849,987 patent/US10294216B2/en active Active
-
2018
- 2018-07-11 US US16/032,858 patent/US10815217B2/en active Active
-
2019
- 2019-03-27 US US16/366,103 patent/US11142515B2/en active Active
- 2019-06-26 AU AU2019204525A patent/AU2019204525B2/en active Active
- 2019-09-05 JP JP2019162164A patent/JP6952085B2/ja active Active
- 2019-12-05 JP JP2019220267A patent/JP6841891B2/ja active Active
-
2020
- 2020-09-24 US US17/031,190 patent/US11634406B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505794A5 (cg-RX-API-DMAC10.html) | ||
| JP6952085B2 (ja) | キナーゼ阻害剤としてのピラゾリル尿素 | |
| RU2401265C2 (ru) | Соединения и композиции в качестве ингибиторов протеинкиназы | |
| SA516370384B1 (ar) | مركبات فعّالة علاجياً وطرق استخدامها | |
| RU2009120389A (ru) | Гетероциклические соединения в качестве противовоспалительных агентов | |
| JP2013510876A5 (cg-RX-API-DMAC10.html) | ||
| RU2016108753A (ru) | Ингибиторы ферментов | |
| RU2011142654A (ru) | Антагонисты гистаминовых н3-рецепторов | |
| JP2012501312A5 (cg-RX-API-DMAC10.html) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| RU2020140891A (ru) | Производные пиразола в качестве ингибиторов калликреина | |
| JP2022534751A (ja) | Ｐ２ｘ３阻害剤としてのアミノキナゾリン誘導体 | |
| RU2011137399A (ru) | Гетероциклическое производное | |
| JP2017502033A5 (cg-RX-API-DMAC10.html) | ||
| JP7699595B2 (ja) | 統合的ストレス応答経路の調節因子 | |
| RU2006105716A (ru) | Производные пиридазина и их применение в качестве терапевтических средств | |
| JP2019505595A5 (cg-RX-API-DMAC10.html) | ||
| RU2006126974A (ru) | Амидное производное и лекарственное средство | |
| RU2016136116A (ru) | Фармацевтические соединения | |
| CA2785113A1 (en) | Imidazopyridine derivatives as jak inhibitors | |
| JP2010510319A5 (cg-RX-API-DMAC10.html) | ||
| RU2018131766A (ru) | 6-гетероциклил-4-морфолин-4-илпиридин-2-оны, пригодные для лечения рака и диабета | |
| RU2013135477A (ru) | Гетероциклические соединения и их применение в качестве ингибиторов киназы-3 гликогенсинтазы | |
| HRP20192151T1 (hr) | Derivati izokromena kao inhibitori fosfoinozitid 3-kinaza | |
| RU2015116532A (ru) | Ингибиторы тирозинкиназы syk |